menu
    • menu

    Company profile for QED Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    A subsidiary of BridgeBio, QED focuses on precision medicine for FGFR-driven cancers and conditions. We live by our name: QED, derived from the Latin “Quod Erat Demonstrandum” —Thus, It Has Been Proven.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    QED TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    75 Federal Street San Francisco, CA 94107
    Telephone
    Telephone
    1-877-280-5655
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://qedtx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    WITHDRAWN: FDA accelerated approval to infigratinib for metastatic cholangiocarcinoma
    WITHDRAWN: FDA accelerated approval to infigratinib for metastatic cholangiocarcinoma

    18 May 2024

    // FDA

    https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma#:~:text=On%20May%2028%2C%202021%2C%20the,2%20(FGFR2)%20fusion%20or%20other

    FDA
    18 May 2024
    Share Share
    LianBio inks $325M IPO for pipeline with BMS, BridgeBio, Lyra
    LianBio inks $325M IPO for pipeline with BMS, BridgeBio, Lyra

    01 Nov 2021

    // Kyle LaHucik FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/lianbio-snags-325m-ipo-slightly-bigger-than-multi-partnered-biotech-s-2020-series-a

    Kyle LaHucik FIERCEBIOTECH
    01 Nov 2021
    Share Share
    BridgeBio grabs a second priority review for the portfolio — giving Perceptive
    BridgeBio grabs a second priority review for the portfolio — giving Perceptive

    02 Dec 2020

    // ENDPTS

    https://endpts.com/bridgebio-grabs-a-second-priority-review-for-the-portfolio-giving-perceptive-startup-cause-to-celebrate/

    ENDPTS
    02 Dec 2020
    Share Share
    BridgeBio Pharma & Affiliate QED Announce FDA Acceptance NDA for Infigratinib
    BridgeBio Pharma & Affiliate QED Announce FDA Acceptance NDA for Infigratinib

    01 Dec 2020

    // GLOBENEWSWIRE

    http://www.globenewswire.com/news-release/2020/12/01/2137349/0/en/BridgeBio-Pharma-and-Affiliate-QED-Therapeutics-Announce-FDA-Acceptance-of-New-Drug-Application-for-Infigratinib-for-the-Treatment-of-Cholangiocarcinoma.html

    GLOBENEWSWIRE
    01 Dec 2020
    Share Share
    Ivy Brain Tumor Center and BridgeBio Pharma’s QED Announce Dosing
    Ivy Brain Tumor Center and BridgeBio Pharma’s QED Announce Dosing

    28 Jul 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/07/28/2068546/0/en/Ivy-Brain-Tumor-Center-and-BridgeBio-Pharma-s-QED-Therapeutics-Announce-Dosing-of-First-Patient-in-Investigator-Initiated-Phase-0-2-Clinical-Trial-of-Infigratinib-in-Recurrent-Glio.html

    GLOBENEWSWIRE
    28 Jul 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search